
Key Points
- 01EU committee backs Baxfendy for adults with uncontrolled hypertension
- 02If approved, Baxfendy would be the EU’s first aldosterone synthase inhibitor
- 03Phase III trials showed up to 14.0 mmHg placebo-adjusted SBP reduction at 12 weeks
- 04Over 70% on Baxfendy hit 24-hour SBP below 130 mmHg in resistant hypertension
EU committee issues positive opinion for Baxfendy
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Baxfendy (baxdrostat) for the treatment of hypertension in adults. The opinion specifically covers arterial hypertension that remains insufficiently controlled despite treatment with at least two antihypertensive medicines. A final European Commission decision is still pending before Baxfendy can be marketed across the EU.
If approved, Baxfendy would be the first and only aldosterone synthase inhibitor available in the EU. It directly targets aldosterone, a hormone that can raise blood pressure to unhealthy levels, to address a key biological driver of elevated blood pressure. The medicine is already approved in the US and other countries for adults whose hypertension is not adequately controlled on other therapies.
Clinical evidence from Phase III BaxHTN and Bax24
The CHMP’s positive opinion is supported by two pivotal Phase III trials, BaxHTN and Bax24, in patients with uncontrolled or resistant hypertension. In BaxHTN, 796 patients were randomised to Baxfendy 2 mg, 1 mg or placebo once daily on top of standard of care for 12 weeks. At week 12, the 2 mg dose produced an absolute reduction of 15.7 mmHg in mean seated systolic blood pressure from baseline and a placebo-adjusted reduction of 9.8 mmHg, with statistical significance.
The Bax24 trial enrolled 218 patients with resistant hypertension, randomising them to Baxfendy 2 mg or placebo on top of standard therapy during a 12-week double-blind period. At week 12, Baxfendy achieved an absolute reduction of 16.6 mmHg in ambulatory 24-hour average systolic blood pressure from baseline and a placebo-adjusted reduction of 14.0 mmHg. Blood-pressure reductions were observed throughout the 24-hour period, including early morning.
In a key secondary endpoint in Bax24, 70.6% of patients treated with Baxfendy reached an ambulatory 24-hour average systolic blood pressure below 130 mmHg, compared with 16.7% on placebo. This translated to two patients needing treatment with Baxfendy rather than placebo for one additional patient to achieve that threshold at week 12.
Longer-term efficacy and safety profile
A post-hoc analysis of BaxHTN showed that the 2 mg dose of Baxfendy sustained a placebo-adjusted seated systolic blood-pressure reduction of 12.6 mmHg over 52 weeks. Long-term safety at week 52, followed by a safety follow-up, was consistent with findings during the 12-week double-blind period. Baxfendy was generally characterised as well tolerated in clinical development.
In the BaxHTN study, potassium levels above 6.0 mmol per litre occurred in 2.3% of patients on the 1 mg dose, 3.0% on the 2 mg dose and 0.4% on placebo. No unanticipated safety findings were reported. Clinical trials also observed significant reductions in aldosterone levels without affecting cortisol across a wide range of Baxfendy doses.
Unmet need in uncontrolled hypertension and next steps
AstraZeneca estimates that about 70 million adults in Europe live with hypertension that remains uncontrolled despite treatment, highlighting the potential patient population for the proposed indication. Dr Bryan Williams said a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events such as heart attack and stroke.
Baxfendy is part of a broader development programme exploring its role in conditions where high aldosterone contributes to elevated cardiovascular and renal risk. Ongoing trials are assessing baxdrostat as monotherapy for primary aldosteronism, in combination with dapagliflozin for chronic kidney disease and hypertension, and for the prevention of heart failure in patients with hypertension. Within the EU, the medicine remains pending a final decision that will determine whether the CHMP’s recommendation translates into full marketing authorisation.
Key Takeaways
- 01Baxfendy has cleared a key EU regulatory hurdle but still awaits a final marketing authorisation decision.
- 02Phase III data show consistent, statistically significant blood-pressure reductions in uncontrolled and resistant hypertension.
- 03If approved, Baxfendy would introduce a new aldosterone-targeting mechanism for EU hypertension patients whose condition remains uncontrolled.
- 04Trial findings suggest a sustained efficacy and a generally manageable safety profile over both 12 and 52 weeks.
References
- https://www.securities.io/chmp-backs-astrazenecas-baxfendy-for-uncontrolled-hypertension/
- https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026
- https://www.astrazeneca.com/media-centre/press-releases/2026/baxfendy-recommended-for-approval-in-the-eu.html
- https://rallies.ai/news/astrazenecas-baxfendy-wins-eu-panel-backing-for-uncontrolled-hypertension-f6bea59455cd4d41